Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Berglind

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Lupus Science & Medicine|April 13, 2018
Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteersRaj Tummala, Tomas Rouse, Anna Berglind, et al.
Orphanet Journal of Rare Diseases|May 24, 2018
Improving the analysis of composite endpoints in rare disease trialsMartina McMenamin, Anna Berglind, James M S Wason
Statistical Methods in Medical Research|November 25, 2020
Employing a latent variable framework to improve efficiency in composite endpoint analysisMartina McMenamin, Jessica K Barrett, Anna Berglind, et al.
Annals of the Rheumatic Diseases|October 31, 2018
Response to: 'Comment on: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by IsenbergEric F Morand, Teodora Trasieva, Anna Berglind, et al.
BMC Rheumatology|December 7, 2021
Increasing power in the analysis of responder endpoints in rheumatology: a software tutorialMartina McMenamin, Michael J Grayling, Anna Berglind, et al.
Annals of the Rheumatic Diseases|February 9, 2018
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: <i>post-hoc</i> analysis of the Phase IIb MUSE trial of anifrolumabEric F Morand, Teodora Trasieva, Anna Berglind, et al.
Statistics in Medicine|February 24, 2022
Sample size estimation using a latent variable model for mixed outcome co-primary, multiple primary and composite endpointsMartina E McMenamin, Jessica K Barrett, Anna Berglind, et al.
Pharmaceutical Statistics|January 11, 2020
What matters most? Different stakeholder perspectives on estimands for an invented case study in COPDOliver N Keene, Stephen Ruberg, Alexander Schacht, et al.
BMJ Open|September 3, 2020
Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signatureEdward R Hammond, Raj Tummala, Anna Berglind, et al.
Antimicrobial Agents and Chemotherapy|April 16, 2014
Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infectionKaren D Sims, Julie Lemm, Timothy Eley, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Lupus Science & Medicine|April 13, 2018
Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteersRaj Tummala, Tomas Rouse, Anna Berglind, et al.
Orphanet Journal of Rare Diseases|May 24, 2018
Improving the analysis of composite endpoints in rare disease trialsMartina McMenamin, Anna Berglind, James M S Wason
Statistical Methods in Medical Research|November 25, 2020
Employing a latent variable framework to improve efficiency in composite endpoint analysisMartina McMenamin, Jessica K Barrett, Anna Berglind, et al.
Annals of the Rheumatic Diseases|October 31, 2018
Response to: 'Comment on: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by IsenbergEric F Morand, Teodora Trasieva, Anna Berglind, et al.
BMC Rheumatology|December 7, 2021
Increasing power in the analysis of responder endpoints in rheumatology: a software tutorialMartina McMenamin, Michael J Grayling, Anna Berglind, et al.
Annals of the Rheumatic Diseases|February 9, 2018
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: <i>post-hoc</i> analysis of the Phase IIb MUSE trial of anifrolumabEric F Morand, Teodora Trasieva, Anna Berglind, et al.
Statistics in Medicine|February 24, 2022
Sample size estimation using a latent variable model for mixed outcome co-primary, multiple primary and composite endpointsMartina E McMenamin, Jessica K Barrett, Anna Berglind, et al.
Pharmaceutical Statistics|January 11, 2020
What matters most? Different stakeholder perspectives on estimands for an invented case study in COPDOliver N Keene, Stephen Ruberg, Alexander Schacht, et al.
BMJ Open|September 3, 2020
Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signatureEdward R Hammond, Raj Tummala, Anna Berglind, et al.
Antimicrobial Agents and Chemotherapy|April 16, 2014
Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infectionKaren D Sims, Julie Lemm, Timothy Eley, et al.
Pageof 2